Northern Trust
VIRX

Northern Trust’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Northern Trust’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,104
Closed -$6.13K – 4544
2024
Q4 		$6.13K Hold
38,104
– – ﹤0.01% 4436
2024
Q3 		$8.82K Hold
38,104
– – ﹤0.01% 4388
2024
Q2 		$20.7K Sell
38,104
-86
-0.2% -$68 ﹤0.01% 4329
2024
Q1 		$39K Buy
38,190
+1,729
+5% +$1.26K ﹤0.01% 4261
2023
Q4 		$20.8K Hold
36,461
– – ﹤0.01% 4360
2023
Q3 		$37.9K Sell
36,461
-2,050
-5% -$2.78K ﹤0.01% 4229
2023
Q2 		$54.3K Sell
38,511
-198
-0.5% -$283 ﹤0.01% 4204
2023
Q1 		$61.5K Buy
38,709
+1,389
+4% +$2.52K ﹤0.01% 4211
2022
Q4 		$54.5K Hold
37,320
– – ﹤0.01% 4265
2022
Q3 		$159K Buy
37,320
+3,793
+11% +$16.1K ﹤0.01% 3968
2022
Q2 		$130K Sell
33,527
-245,099
-88% -$698K ﹤0.01% 4074
2022
Q1 		$1.33M Sell
278,626
-14,866
-5% -$44.8K ﹤0.01% 3295
2021
Q4 		$1.07M Sell
293,492
-8,604
-3% -$45.9K ﹤0.01% 3515
2021
Q3 		$2.42M Sell
302,096
-11,254
-4% -$111K ﹤0.01% 3182
2021
Q2 		$3.55M Buy
313,350
+300,148
+2,274% +$3.01M ﹤0.01% 3044
2021
Q1 		$122K Buy
13,202
+4,969
+60% +$51.8K ﹤0.01% 4240
2020
Q4 		$57K Buy
8,233
+1,628
+25% +$8.5K ﹤0.01% 4218
2020
Q3 		$28K Buy
6,605
+447
+7% +$3.9K ﹤0.01% 4170
2020
Q2 		$57K Sell
6,158
-78
-1% -$1.18K ﹤0.01% 4038
2020
Q1 		$90K Sell
6,236
-61
-1% -$1.32K ﹤0.01% 3839
2019
Q4 		$75K Sell
6,297
-8
-0.1% -$134 ﹤0.01% 3990
2019
Q3 		$159K Buy
6,305
+1,569
+33% +$45.3K ﹤0.01% 3812
2019
Q2 		$120K Buy
4,736
+1,676
+55% +$64.8K ﹤0.01% 3933
2019
Q1 		$130K Buy
3,060
+1,037
+51% +$23.5K ﹤0.01% 3868
2018
Q4 		$30K Buy
2,023
+6
+0.3% +$245 ﹤0.01% 4120
2018
Q3 		$142K Buy
2,017
+73
+4% +$5.54K ﹤0.01% 3950
2018
Q2 		$144K Buy
1,944
+39
+2% +$3.47K ﹤0.01% 3935
2018
Q1 		$181K Sell
1,905
-14
-0.7% -$2.4K ﹤0.01% 3849
2017
Q4 		$248K Buy
1,919
+1,038
+118% +$97.3K ﹤0.01% 3743
2017
Q3 		$60K Buy
881
+1
+0.1% +$82 ﹤0.01% 4037
2017
Q2 		$84K Sell
880
-15
-2% -$1.72K ﹤0.01% 4008
2017
Q1 		$128K Buy
895
+204
+30% +$29.2K ﹤0.01% 3903
2016
Q4 		$87K Buy
691
+243
+54% +$33.8K ﹤0.01% 3934
2016
Q3 		$69K Buy
448
+26
+6% +$3.67K ﹤0.01% 3957
2016
Q2 		$49K Sell
422
-36
-8% -$3.99K ﹤0.01% 4018
2016
Q1 		$54K Hold
458
– – ﹤0.01% 4010
2015
Q4 		$87K Hold
458
– – ﹤0.01% 3964
2015
Q3 		$78K Sell
458
-1,870
-80% -$675K ﹤0.01% 3994
2015
Q2 		$1.47M Sell
2,328
-110
-5% -$58.5K ﹤0.01% 3200
2015
Q1 		$1.25M Buy
2,438
+3
+0.1% +$1.51K ﹤0.01% 3330
2014
Q4 		$1.3M Sell
2,435
-85
-3% -$38.3K ﹤0.01% 3303
2014
Q3 		$3.78M Buy
2,520
+416
+20% +$602K ﹤0.01% 2693
2014
Q2 		$2.88M Buy
2,104
+103
+5% +$120K ﹤0.01% 2871
2014
Q1 		$2.78M Sell
2,001
-158
-7% -$184K ﹤0.01% 2940
2013
Q4 		$2.15M Buy
2,159
+79
+4% +$81.7K ﹤0.01% 3108
2013
Q3 		$2.17M Buy
2,080
+96
+5% +$103K ﹤0.01% 3043
2013
Q2 		$2.16M Buy
+1,984
New +$2.21M ﹤0.01% 2940

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Northern Trust's VIRX Position: Q1 2025 in Review

Northern Trust sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 38,104 shares — an estimated $6.13K sold.

Northern Trust first reported a position in VIRX in Q2 2013 and held it in 47 quarters. The position peaked at $3.78M in Q3 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Northern Trust reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Northern Trust sold 38,104 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $6.13K.
  • Northern Trust first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 47 quarters.
  • Northern Trust's Viracta Therapeutics, Inc. Common Stock position peaked at $3.78M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.